An electrochemical outlook on tamoxifen biotransformation: Current and future prospects

Current Drug Metabolism

Volumn 12, Issue 4, 2011, Pages 372-382

  Garrido, Jorge M P J ^a,b   Garrido, E Manuela P J ^a,b   Oliveira Brett, Ana Maria ^c   Borges, Fernanda ^b  

^a INSTITUTO SUPERIOR DE ENGENHARIA DO PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Biotransformation; Breast cancer; DNA; Electrochemistry; Sensor; Tamoxifen

Indexed keywords

ANTIESTROGEN; CYTOCHROME P450 2D6; DRUG METABOLITE; GLUTATHIONE; LIPID; PIPENDOXIFENE; TAMOXIFEN;

AGONIST; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DNA DAMAGE; DRUG DETERMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; ELECTROCHEMICAL ANALYSIS; ELECTROCHEMISTRY; ENDOMETRIUM; ESTROGEN ACTIVITY; GENOTOXICITY; HUMAN; LIPID BLOOD LEVEL; MITOSIS INHIBITION; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; VAGINA EPITHELIUM;

EID: 79953669463     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795202965     Document Type: Article

References (76)

1. Rossi, A.; Colantuoni, G.; Maione, P.; Ferrara, C.; Airoma, G.; Barzelloni, M.L.; Castaldo; V.; Gridelli, C. Chemotherapy of breast cancer in the elderly. Curr. Med. Chem., 2005, 12, 297-310. (Pubitemid 40305621)
2. Musa, M.A.; Khan, M.O.F.; Cooperwood, J.S. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr. Med. Chem., 2007, 14, 1249-1261. (Pubitemid 46739325)
3. Powles, T.J. Efficacy of tamoxifen as treatment of breast cancer. Semin. Oncol., 1997, 24 (Suppl. 1), 48-54.
4. MacGregor, J.I.; Jordan, V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 1998, 50 (2), 151-196 and references herein. (Pubitemid 28305723)
5. Singh, M.N.; Stringfellow, H.F.; Paraskevaidis, E.; Martin-Hirsch, P.L.; Martin, F.L. Tamoxifen: important considerations of a multifunctional compound with organ-specific properties. Cancer Treat. Rev., 2007, 33, 91-100. (Pubitemid 46323395)
6. Baum, M. Tamoxifen -the treatment of choice. Why look for alternatives? Br. J. Cancer, 1998, 78 (Suppl. 4), 1-4.
7. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Pic-cart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst., 2005, 97, 1262-1271. (Pubitemid 41535367)
8. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wol-mark, N. Tamoxifen for the prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst., 1998, 90, 1371-1388. (Pubitemid 28439961)
9. Cuzick, J.; Powles, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breast-cancer prevention trials. Lancet, 2003, 361, 296-300. (Pubitemid 36126189)
10. Smith, L.L; Brown, K.; Carthew, P.; Lim, C.-K.; Martin, E.A.; Styles, J.; White, I.N.H. Chemoprevention of breast cancer by ta-moxifen: risks and opportunities. Crit. Rev. Toxicol., 2000, 30, 571-594.
11. Brown, K. Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, 2009, 24, 391-404.
12. Turken, S.; Siris, E.; Seldin, D.; Flaster, E.; Hyman, G.; Lindsay, R. Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst., 1989, 81, 1086-1088. (Pubitemid 19175144)
13. Gylling, H.; Pyrhonen, S.; Mantyla, E.; Maenpaa, H.; Kangas, L.; Miettinen, T. A. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholestenol conversion to lathosterol in women with breast cancer. J. Clin. Oncol., 1995, 13, 2900-2905.
14. Ruenitz, P.C. Drugs for osteoporosis prevention: mechanisms of bone maintenance. Curr. Med. Chem., 1995, 2, 791-802. (Pubitemid 26024163)
15. Badia, E.; Oliva, J.; Balaguer, P.; Cavailles, V. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr. Med. Chem., 2007, 14, 3035-3043. (Pubitemid 350226972)
16. White, I.N.H. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab., 2003, 4, 223-239 and references herein. (Pubitemid 36656480)
17. Desta, Z.; Ward, B.A.; Soukhova, N.V.; Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 2004, 310, 1062-1075. (Pubitemid 39108928)
18. Kim, S.Y.; Laxmi, Y.R.S.; Suzuki, N.; Ogura, K.; Watabe, T.; Duffel, M.W.; Shibutani, S. Formation of tamoxifen-DNA adducts via o-sulfonation, not o-acetylation, of a-hydroxytamoxifen in rat and human livers. Drug Metab. Dispos. (Pubitemid 41539966)
19. Chen, G.; Yin, S.; Maiti, S.; Shao, X. 4-Hydroxytamoxifen sulfation metabolism. J. Biochem. Mol. Toxicol., 2002, 16, 279-285.
20. Zhang, F.; Fan, P.W.; Liu, X.; Shen, L.; van Breemen, R.B.; Bol-ton, J.L. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol., 2000, 13, 53-62. (Pubitemid 30055959)
21. Kuramochi, H. Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem., 1996, 39, 2877-2886. (Pubitemid 26251025)
22. Costa, G.G.; Marques, M.M.; Beland, F.A.; Freeman, J.P.; Churchwell, M.I.; Doerge, D.R. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol., 2003, 16, 357-366. (Pubitemid 36373700)
23. Kim, S.Y.; Suzuki, N.; Laxmi, Y.R.S.; Shibutani, S. Inefficient repair of tamoxifen-DNA adducts in rats and mice. Drug Metab. Dispos. (Pubitemid 43145033)
24. Zheng, Y.; Sun, D.; Sharma, A.K.; Chen, G.; Amin, S.; Lazarus, P. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab. Dispos. (Pubitemid 47481590)
25. Ferraldeschi, R.; Newman, W.G. The impact of CYP2D6 genotyping on tamoxifen treatment. Pharmaceuticals, 2010, 3, 1122-1138.
26. Wegman, P.; Vainikka, L.; Stål, O.; Nordenskjöld, B.; Skoog, L.; Rutqvist, L.-E.; Wingren, S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res., 2005, 7, R284-R290.
27. Kumar, G.N.; Surapaneni, S. Role of drug metabolism in drug discovery and development. Med. Res. Rev., 2001, 21, 397-411. (Pubitemid 32751462)
28. Fura, A.; Shu, Y.-Z.; Zhu, M.; Hanson, R.L.; Roongta, V.; Humphreys, W.G. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J. Med. Chem., 2004, 47, 4339-4351. (Pubitemid 39096823)
29. Fura, A. Role of pharmacologically active metabolites in drug discovery and development. Drug Discov. Today, 2006, 11 , 133-142. (Pubitemid 43375964)
30. Chen, Y.; Monshouwer, M.; Fitch, W.L. Analytical tools and approaches for metabolite identification in early drug discovery. Pharm. Res., 2007, 24, 248-257.
31. Lohmann, W.; Karst, U. Biomimetic modeling of oxidative drug metabolism. Strategies, advantages and limitations. Anal. Bioanal. Chem., 2008, 391, 79-96.
32. Shu, Y.-Z.; Johnson, B.M.; Yang, T.J. Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. AAPS J., 2008, 10, 178-192.
33. Kissinger, P.T.; Heineman, W.R. Laboratory Techniques in Elec-troanalytical Chemistry, Marcel Dekker: New York, 1996.
34. Brajter-Toth, A.; Chambers, J.Q. Electroanalytical Methods for Biological Materials, Marcel Dekker: New York, 2002.
35. Özkan, S.A.; Uslu, B.; Aboul-Enein, H.Y. Analysis of pharmaceuticals and biological fluids using modern electroanalytical techniques. Crit. Rev. Anal. Chem., 2003, 33, 155-181.
36. Milhazes, N.; Martins, P.; Uriarte, E.; Garrido, J.; Calheiros, R.; Marques, M.P.M.; Borges, F. Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4- methylenedioxymethamphetamine (MDMA) and its synthetic precursors. Anal. (Pubitemid 47039235)
37. Radi, A.-E. Recent updates of chemically modified electrodes in pharmaceutical analysis. Comb. Chem. High Throughput Screen., 2010, 13, 728-752.
38. Eckert, G.M.; Gutmann, F.; Keyzler, H. Electropharmacology, CRC Press: Boca Raton, 1990.
39. Dryhurst, G.; Kadish, K.M.; Shceller, F.; Renneberg, R. Biological Electrochemistry, Academic Press: New York, 1982.
40. Berry, M.N. An electrochemical interpretation of metabolism. FEBS Lett., 1981, 134, 133-138.
41. Abreu, F.C.; Ferraz, P.A.L.; Goulart, M.O.F. Some applications of electrochemistry in biomedical chemistry. Emphasis on the correlation of electrochemical and bioactive properties. J. Braz. Chem. Soc., 2002, 13, 19-35.
42. Meyer, D.F.; Gamache, P.H.; Acworth, I.N. In: Metabolome Analyses: Strategies for Systems Biology, Vaidyanathan, S.; Har-rigan, G.G.; Goodacre, R., Eds.; Springer: New York, 2005; Ch. 8, pp. 119-135.
43. Karst, U. Electrochemistry/mass spectrometry (EC/MS) -A new tool to study drug metabolism and reaction mechanisms. Angew. Chem. Int. Ed., 2004, 43, 2476-2478. (Pubitemid 39257706)
44. Deng, H.T.; Van Berkel, G.J. A thin-layer electrochemical flow cell coupled on-line with electrospray-mass spectrometry for the study of biological redox reactions. Electroanalysis, 1999, 11, 857-865.
45. Johansson, T.; Weidolf, L.; Jurva, U. Mimicry of phase I drug metabolism -novel methods for metabolite characterization and synthesis. Rapid Commun. Mass Spectrom., 2007, 21, 2323-2331. (Pubitemid 47121164)
46. Korfmacher, W.A., Ed. Using mass spectrometry for drug metabolism studies, CRC Press: Boca Raton, Florida, 2005.
47. Staack, R.F.; Hopfgartner, G. New analytical strategies in studying drug metabolism. Anal. (Pubitemid 47150867)
48. Kalgutkar, A.S.; Gardner, I.; Obach, R.S.; Shaffer, C.L.; Callegari, E.; Henne, K.R.; Mutlib, A.E.; Dalvie, D.K.; Lee, J.S.; Nakai, Y.; O'Donnell, J.P.; Boer, J.; Harriman, S.P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225. (Pubitemid 40753853)
49. Walgren, J.L.; Mitchell, M.D.; Thompson, D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxi-col., 2005, 35, 325-361. (Pubitemid 40691298)
50. Liebler, D.C.; Guengerich, F.P. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov., 2005, 4, 410-420. (Pubitemid 40704124)
51. Jurva, U.; Wikstrom, H. V.; Bruins, A. P. In vitro mimicry of metabolic oxidation reactions by electrochemistry/mass spectrome-try. Rapid Commun. Mass Spectrom., 2000, 14, 529-533. (Pubitemid 30153006)
52. Permentier, H.P.; Bruins, A.P.; Bischoff, R. Electrochemistry-Mass spectrometry in drug metabolism and protein research. Mini Rev. Med. Chem., 2008, 8, 46-56. (Pubitemid 351320929)
53. Alvarez-Lueje, A.; Dragnic, S. B. Stability and drug metabolism assessed by electrochemical methods. Comb. Chem. High Throughput Screen., 2010, 13, 712-727.
54. Lohmann, W.; Karst, U. Electrochemistry meets enzymes: instrumental on-line simulation of oxidative and conjugative metabolism reactions of toremifene. Anal. Bioanal. Chem., 2009, 394, 1341-1348.
55. Odijk, M.; Baumann, A.; Lohmann, W.; van den Brink, F. T. G.; Olthuis, W.; Karst, U.; van den Berg, A. A microfluidic chip for electrochemical conversions in drug metabolism studies. Lab Chip, 2009, 9, 1687-1693.
56. Lohmann, W.; Baumann, A; Karst, U. Electrochemistry and LC-MS for metabolite generation and identification: tools, technologies and trends. LC GC Eur., 2010, 23, 8-16.
57. Fojta, M. Electrochemical sensors for DNA interactions and damage. Electroanalysis, 2002, 14, 1449-1463.
58. Palecek, E.; Fojta, M.; Jelen, F.; Vetterl, V. In: The Encyclopedia of Electrochemistry, Bard, A.J.; Stratsmann, M., Eds.; Wiley-VCH: Weinheim, 2002; Vol. 9, pp. 365-429.
59. Kerman, K.; Kobayashi, M.; Tamiya, E. Recent trends in electrochemical DNA biosensor technology. Meas. Sci. Technol., 2004, 15, R1-R11. (Pubitemid 38261613)
60. Oliveira-Brett, A.M. In: Encyclopedia of Sensors, Grimes, C.A.; Dickey, E.C.; Pishko, M.V., Eds.; American Scientific Publishers: California, 2006; Vol. 3, pp. 301-314.
61. Oliveira Brett, A.M.; Diculescu, V.; Chiorcea-Paquim, A.M.; Serrano. S.H.P. In: Comprehensive Analytical Chemistry (CAC), Ale-gret, S.; Merkoci, A., Eds.; Elsevier: Amsterdam, 2007, Vol. 49, pp. 413-437.
62. Oliveira-Brett, A.M. In: Bioelectrochemistry: Fundamentals, Experimental Techniques and Applications, Bartlett, P.N., Ed.; John Wiley: Chichester, 2008, pp. 411-442.
63. Fijalek, Z.; Chodkowski, J.; Warowna, M. Polarographic studies of drugs of triphenylethene derivatives. J. Electroanal. Chem., 1987, 226, 129-136.
64. Wang, J.; Cai, X.; Fernandes, J.R.; Ozsoz, M.; Grant, D.H. Adsorp-tive potentiometric stripping analysis of trace tamoxifen at a glassy carbon electrode. Talanta, 1997, 45, 273-278. (Pubitemid 27506664)
65. Guo, X.-X.; Song, Z.-J.; Tian, X.-J.; Song, J.-F. Single-sweep voltammetric determination of tamoxifen at carbon paste electrode. Anal. (Pubitemid 351990063)
66. Stuart, J.D.; Ohnesorge, W.E. Electrochemical oxidation of phen-ylethylenes. I. Conversion of tetraphenylethylene to 9,10- diphenylphenanthrene. J. Am. Chem. Soc., 1971, 93, 45 31-45 36.
67. Schreivogel, A.; Maurer, J.; Winter, R.; Baro, A.; Laschat, S. Synthesis and electrochemical properties of tetrasubstituted tetraphen-ylethenes. Eur. J. Org. Chem., 2006, 3395-3404.
68. Lund, H.; Baiser, M. M., Ed. Organic Electrochemistry, 3rd ed.; Marcel Dekker: New York, 1991.
69. Garrido, J.M.P.J.; Delerue-Matos, C.; Borges, F.; Macedo, T.R.A.; Oliveira-Brett, A.M. New insights into the oxidation pathways of apomorphine. J. Chem. Soc., Perkin Trans., 2002, 2, 1713-1717. (Pubitemid 35289447)
70. Garrido, E.M.P.J.; Garrido, J.M.P.J.; Esteves, M.; Santos-Silva, A.; Marques, M.P.M.; Borges, F. Voltammetric and DFT studies on viloxazine: analytical application to pharmaceuticals and biological fluids. Electroanalysis, 2008, 20, 1454-1462.
71. Garrido, E.M.; Garrido, J.; Calheiros, R.; Marques, M.P.M.; Borges, F. Fluoxetine and norfluoxetine revisited: new insights into the electrochemical and spectroscopic properties. J. Phys. Chem. A., 2009, 773, 9934-9944.
72. Chamart, S.; Hanocq, M.; Helson, M.; Devleeschouwer, N.; Le-clercq, G. Determination of 2-methyl derivatives of tamoxifen in cell culture medium using high-performance liquid chromatogra-phy and electrochemical detection. J. Chromatogr. B., 1989, 496, 365-375. (Pubitemid 20010702)
73. Daneshgar, P.; Norouzi, P.; Ganjali, M.R.; Zamani, H.A. Ultrasensitive flow-injection electrochemical method for detection of anti-cancer drug tamoxifen. Talanta, 2009, 77, 1075-1080.
74. Zhao, L.; Krishnan, S.; Zhang, Y.; Schenkman, J.B.; Rusling, J.F. Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors. Chem. Res. Toxicol., 2009, 22, 341-347.
75. Wang, J. Electrochemical biosensors: towards point of care cancer diagnostics. Biosens. Bioelectron., 2006, 27, 1887-1892.
76. Tothill, I.E. Biosensors for cancer markers diagnosis. Semin. Cell Dev. Biol., 2009, 20, 55-62.